Pharmaceutical Secondary Packaging Market Size, Share and Forecast 2032

Market Overview

Pharmaceutical Secondary Packaging Market size was valued USD 43,273.30 Million in 2024 and is anticipated to reach USD 61,727.68 Million by 2032, at a CAGR of 4.54% during the forecast period.

The pharmaceutical secondary packaging market is led by key players including Gerresheimer, Berry Global, Schreiner MediPharm, Graphic Packaging International, Amcor, Metsä Board, Constantia Flexibles, DS Smith, Stevanato, Körber Pharma Packaging, Marchesini, WestRock, Sonoco, Huhtamaki, and CCL Industries. These companies focus on innovative folding cartons, blister cards, and smart labeling solutions to meet global serialization and sustainability standards. North America emerged as the leading region, accounting for nearly 38% of the market share in 2024, driven by strong pharmaceutical production, advanced compliance regulations, and rising demand for sustainable and tamper-evident packaging solutions.

Market Insights

• The pharmaceutical secondary packaging market was valued at USD 43,273.30 million in 2024 and is expected to reach USD 61,727.68 million by 2032, growing at a CAGR of 4.54%.
• Growth is driven by regulatory compliance requirements, rising chronic disease prevalence, and demand for tamper-evident and eco-friendly packaging formats such as folding cartons and paperboard boxes.
• Key trends include adoption of smart packaging with RFID and QR codes, increasing automation in packaging lines, and rising use of recyclable and compostable materials to meet sustainability targets.
• Competition is strong with players focusing on innovation, capacity expansion, and partnerships with pharmaceutical companies to offer localized, cost-effective, and compliant packaging solutions.
• North America leads the market with 38% share, followed by Europe at 30% and Asia Pacific at 22%, while folding cartons remain the dominant segment, holding the largest share due to regulatory labeling and serialization needs.

Market Segmentation Analysis:

By Packaging Type

Folding cartons dominated the pharmaceutical secondary packaging market with over 30% share in 2024. Their popularity stems from versatility, cost-effectiveness, and compatibility with automated filling lines. They provide ample space for regulatory labeling and barcodes, supporting serialization compliance under global track-and-trace regulations. Rising demand for child-resistant and tamper-evident designs is driving innovations in folding carton solutions. Growth is also fueled by sustainability trends as manufacturers adopt recyclable paper-based substrates. Blister cards and pouches are gaining traction for single-dose packaging formats, while labels and leaflets remain essential for patient information and drug safety communication.

• For instance, Smurfit-WestRock manufactured 204.4 billion square feet of corrugated packaging in 2024.

By Material

Paperboard held the leading share of more than 35% in 2024, driven by its recyclability and printing flexibility. The material supports high-quality graphics for branding and regulatory compliance. Pharmaceutical companies prefer paperboard for folding cartons and cartons used for biologics and injectables. Corrugated board is used for shipping bulk pharmaceutical products, offering protection during transportation. Plastic usage remains strong in clamshells and blister cards, driven by durability and moisture resistance. Aluminium foil continues to be preferred for moisture-sensitive drugs, while glass-based secondary packaging is niche, primarily for premium injectable presentations and specialty biologics.

• For instance, Mondi’s Duino mill will produce 420,000 tonnes of recycled containerboard per year when fully operational.

By Application

Injectables accounted for the largest share, surpassing 40% in 2024, due to rising biologics and biosimilar launches. Secondary packaging ensures protection, sterility, and proper labeling of vials, prefilled syringes, and ampoules. Demand is rising for tamper-evident cartons and serialized labels to meet regulatory standards like DSCSA and EU FMD. Ophthalmic and respiratory therapy segments are growing with increasing demand for eye drops and inhalers, requiring compact and compliant packaging. Wound care and oral drug segments also contribute steadily, supported by patient-centric designs that improve adherence. Growth is accelerated by increasing chronic disease prevalence and expanding cold-chain logistics.

Market Overview

Regulatory Compliance and Serialization

Regulatory compliance is the key growth driver shaping the pharmaceutical secondary packaging market, influencing design, material selection, and production processes. Global mandates such as the U.S. DSCSA and EU FMD require full product serialization, tamper-evident seals, and robust traceability systems, pushing companies to adopt advanced printing technologies and secure packaging formats. Folding cartons and serialized labels are in higher demand as they offer space for barcodes, QR codes, and patient information. Investments in digital tracking systems have grown, ensuring supply chain transparency and patient safety while reducing risks of counterfeit products and recalls.

• For instance, in a pilot with five high-volume US retail pharmacies, RFXCEL’s serialization and track-and-trace integration yielded 35% better inventory accuracy and 45% faster recall response, and achieved almost full DSCSA compliance.

Rising Chronic Disease Prevalence

The growing prevalence of chronic illnesses such as diabetes, cardiovascular disorders, and cancer continues to accelerate the demand for injectables, biologics, and personalized medicines. These therapies require reliable secondary packaging to ensure sterility, accurate labeling, and protection during transport. Prefilled syringes, ampoules, and vials are increasingly packaged in tamper-evident cartons and trays with clear serialization to meet safety standards. The rising elderly population, higher rates of hospital visits, and expansion of vaccination programs are further fueling demand for secure, easy-to-handle packaging solutions that improve adherence and reduce contamination risks.

• For instance, the number of people with diabetes worldwide is projected to reach 643 million by 2030, with much of the increase in low- and middle-income countries.

Sustainability and Eco-friendly Materials

The global shift toward sustainability is a strong growth driver, with pharmaceutical companies focusing on recyclable and biodegradable packaging materials. Paperboard and compostable substrates are being used to replace plastic-based secondary packaging, aligning with government sustainability regulations and corporate ESG commitments. Manufacturers are investing in eco-friendly coatings, water-based inks, and lightweight designs to minimize carbon footprint without compromising product protection. This transition also appeals to environmentally conscious stakeholders, driving adoption of folding cartons and corrugated board that can be fully recycled, creating a competitive advantage for companies prioritizing green packaging solutions.

Key Trends & Opportunities

Smart and Connected Packaging

Smart packaging is emerging as a transformative trend, integrating QR codes, NFC, and RFID technologies into labels and cartons for enhanced authentication and traceability. This supports real-time supply chain monitoring and combats counterfeiting, a critical issue in pharmaceuticals. Patients benefit from interactive features that provide dosage reminders, educational content, and refill alerts, boosting adherence rates. With increasing demand for transparency, smart packaging is becoming a differentiator for pharmaceutical brands, opening new opportunities for value-added services and building trust with patients and healthcare providers.

• For instance, Tageos increased its annual global production capacity from over 7 billion RFID inlays and tags in 2023 to more than 9 billion by mid-2024, following the opening of new plants in Guangzhou, China, and Fletcher, North Carolina. The company has since grown its capacity to over 11 billion units as of mid-2025.

Growth of Biologics and Biosimilars

The rapid expansion of biologics and biosimilars is creating strong opportunities for specialized secondary packaging solutions. These products often require strict temperature control, moisture protection, and tamper-evident features to maintain efficacy during distribution. Innovation in insulated cartons, high-barrier pouches, and serialized labeling supports the growing demand. Cold-chain packaging solutions are being developed to ensure biologics reach patients safely and in optimal condition, driving investments in materials with enhanced barrier properties and intelligent temperature-monitoring devices integrated into secondary packaging.

• For instance, University of Illinois Health pharmacy tagged nearly 30,000 items using RFID between January and March 2024, averaging about 9,785 items per month.

Outsourcing to Contract Packaging Organizations

Pharmaceutical companies are increasingly outsourcing secondary packaging operations to contract packaging organizations (CPOs) to optimize costs, scale production, and ensure regulatory compliance. CPOs offer specialized capabilities such as serialization, aggregation, and custom packaging design, enabling faster market entry. This trend is especially strong in emerging markets, where local packaging facilities reduce logistics costs and improve lead times. Outsourcing also allows pharma firms to focus on core drug development activities while leveraging the expertise of packaging specialists to meet global quality and safety standards.

Key Challenges

High Packaging Costs

Rising raw material costs, stricter compliance requirements, and the push toward sustainable materials are significantly increasing overall packaging expenses. Lightweight yet durable designs require R&D investments, and incorporating tamper-evident features or serialization adds further cost. For manufacturers with large-scale production, these expenses can impact margins and pricing strategies. Companies are exploring cost optimization through bulk material procurement, automation, and standardization of packaging formats, but balancing cost control with compliance and sustainability goals remains a major challenge.

Regulatory Complexity and Counterfeiting

Navigating diverse regulatory requirements across multiple regions is complex and costly, as companies must frequently upgrade systems to stay compliant with evolving guidelines. Serialization requirements differ between countries, making global standardization difficult. At the same time, counterfeit drugs remain a serious threat, leading to risks of revenue loss and patient harm. Advanced anti-counterfeiting technologies such as holograms, tamper-evident seals, and blockchain-enabled tracking are being implemented, but these solutions demand significant capital investment, adding pressure on pharmaceutical packaging budgets and operations.

Regional Analysis

North America

North America held the largest share of around 38% of the pharmaceutical secondary packaging market in 2024. The region benefits from a strong pharmaceutical manufacturing base, advanced healthcare infrastructure, and strict regulatory requirements like DSCSA. Demand for serialization-ready folding cartons and tamper-evident labels remains high. Growth is driven by rising biologics production and increased adoption of sustainable paperboard packaging. The U.S. leads with major investments in automated packaging lines and smart labeling technologies. Canada supports market expansion with growing government healthcare initiatives and rising demand for high-quality packaging for injectable and specialty medicines.

Europe

Europe accounted for nearly 30% of the market share in 2024, supported by stringent compliance with EU FMD regulations that mandate serialization and tamper-proof packaging. Countries such as Germany, France, and the U.K. drive growth with high pharmaceutical exports and strong adoption of eco-friendly paperboard solutions. Demand for blister cards and folding cartons remains robust due to widespread use of prescription medicines. Increasing focus on sustainability and circular economy policies accelerates adoption of recyclable materials. Expansion of biologics production facilities and growth in contract packaging services further strengthen the regional market outlook.

Asia Pacific

Asia Pacific captured approximately 22% of the market share in 2024 and is the fastest-growing region. Rapid expansion of pharmaceutical manufacturing hubs in India, China, and South Korea drives high demand for cost-effective secondary packaging solutions. Rising population, growing healthcare access, and government investment in medicine distribution programs boost volume demand. Folding cartons and corrugated board packaging dominate due to affordability and scalability. Increasing export of generic drugs and biosimilars from this region encourages adoption of global serialization standards, supporting compliance and supply chain security across international markets.

Latin America

Latin America represented about 6% of the pharmaceutical secondary packaging market in 2024, with growth driven by expanding healthcare coverage and local drug manufacturing. Brazil and Mexico lead in production and consumption, creating demand for affordable and compliant packaging solutions. Adoption of tamper-evident and serialized labeling is rising as regulatory frameworks tighten. Cost-effective folding cartons and pouches remain popular formats for oral and over-the-counter medicines. Growing investments in packaging automation and expansion of pharmaceutical exports are expected to create new opportunities in the coming years, supporting steady regional market development.

Middle East & Africa

Middle East & Africa held nearly 4% share of the market in 2024, driven by increasing pharmaceutical imports and gradual expansion of local manufacturing facilities. Gulf countries such as Saudi Arabia and the UAE are investing in healthcare infrastructure, boosting demand for high-quality secondary packaging. Preference for cartons, leaflets, and labels is growing to ensure compliance with labeling regulations and patient safety requirements. South Africa leads demand in Africa, supported by government immunization programs and local drug packaging initiatives. Rising focus on serialization adoption is expected to support future market growth in the region.

Market Segmentations:

By Packaging Type:

• Folding Cartons
• Paperboard Boxes
• Pouches & Sachets
• Labels & Leaflets
• Blister Cards
• Clamshells
• Wrap-Around Packaging

By Material:

• Paperboard
• Corrugated Board
• Plastics
• Aluminium Foil
• Glass

By Application:

• Ophthalmic
• Injectable
• Biologics
• Wound Care
• Respiratory Therapy
• Oral

By Geography:

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Competitive Landscape

The pharmaceutical secondary packaging market is characterized by the presence of leading players such as Gerresheimer, Berry Global, Schreiner MediPharm, Graphic Packaging International, Amcor, Metsä Board, Constantia Flexibles, DS Smith, Stevanato, Körber Pharma Packaging, Marchesini, WestRock, Sonoco, Huhtamaki, and CCL Industries. These companies focus on product innovation, advanced materials, and compliance with global serialization and sustainability standards. Strategies include expanding production capacity, investing in automated packaging technologies, and developing eco-friendly solutions like recyclable paperboard and biodegradable films. Many players are enhancing global footprints through acquisitions and partnerships with pharmaceutical manufacturers to provide localized supply chain solutions. Digital printing, smart labeling, and tamper-evident features are major areas of focus to improve patient safety and combat counterfeiting. Competitive rivalry remains intense, with emphasis on differentiation through cost efficiency, regulatory compliance, and integration of value-added services such as contract packaging and serialization support to meet growing industry demands.

Key Player Analysis

• Gerresheimer
• Berry Global
• Schreiner MediPharm
• Graphic Packaging International
• Amcor
• Metsä Board
• Constantia Flexibles
• DS Smith
• Stevanato
• Körber Pharma Packaging
• Marchesini
• WestRock
• Sonoco
• Huhtamaki
• CCL Industries

Recent Developments

• In 2025, Marchesini showcased monoblock at the Pharmintech Trade show, solutions that integrate blister packaging with cartoning. The new alternating cartoner was designed to handle a wide range of formats at high speeds, offering pharmaceutical manufacturers the flexibility needed for various product types.
• In 2025, DS Smith unveiled TailorTemp, a fully fiber-based, temperature-controlled secondary packaging solution for pharmaceuticals.
• In 2024, Stevanato Group opened a new 65,000-square-meter plant in Latina, Italy. This facility included advanced production lines, primarily for Ez-fill pre-sterilized syringes, which are key components of pharmaceutical secondary packaging

Report Coverage

The research report offers an in-depth analysis based on Packaging Type, Material, Application and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

1. Demand for serialization-ready packaging will rise due to stricter global compliance requirements.
2. Adoption of recyclable and compostable paperboard solutions will accelerate to meet sustainability goals.
3. Smart packaging with RFID, QR codes, and NFC tags will see wider integration.
4. Growth in biologics and biosimilars will increase demand for cold-chain compatible secondary packaging.
5. Automation in packaging lines will expand to improve efficiency and reduce labor costs.
6. Contract packaging organizations will play a larger role in meeting flexible production needs.
7. Digital printing will gain traction for customization, variable data, and faster turnaround times.
8. Tamper-evident and child-resistant designs will be prioritized to enhance patient safety.
9. Emerging markets will drive strong growth supported by local manufacturing expansion.
10. Investment in anti-counterfeiting technologies will grow to protect supply chains and brand integrity.

Regulatory Compliance and Serialization

Stringent global regulations such as the U.S. DSCSA and EU FMD require serialization, tamper-evident features, and robust traceability in pharmaceutical packaging. This drives demand for advanced secondary packaging solutions that support barcoding, QR codes, and secure labeling to ensure patient safety and supply chain transparency.

Rising Chronic Disease Prevalence

The increasing incidence of chronic diseases like diabetes, cancer, and cardiovascular disorders is boosting demand for injectables and biologics, which require reliable, protective, and compliant secondary packaging to maintain sterility and accurate labeling during distribution.

Sustainability and Eco-friendly Materials

Pharmaceutical companies are under pressure to adopt recyclable and biodegradable packaging materials to meet regulatory and corporate sustainability goals. This is accelerating the shift toward paperboard and compostable substrates in secondary packaging, appealing to environmentally conscious stakeholders.

Growth of Biologics and Biosimilars

The rapid expansion of biologics and biosimilars necessitates specialized secondary packaging that ensures temperature control, moisture protection, and tamper evidence. This trend is driving innovation in insulated cartons, high-barrier pouches, and smart labeling for cold-chain logistics.

Smart and Connected Packaging

Integration of RFID, QR codes, and NFC technologies into secondary packaging is enhancing authentication, traceability, and patient engagement. Smart packaging supports real-time supply chain monitoring and combats counterfeiting, providing added value for pharmaceutical brands and healthcare providers.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.